CSPC obtains approval for mesalazine enteric-coated tablets
CSPC Pharmaceutical Group Limited announced that its Mesalazine Enteric-Coated Tablets (0.5g) have received drug registration approval from the National Medical Products Administration of the People's Republic of China. The tablets have also passed the consistency evaluation of quality and efficacy for generic drugs. The drug treats ulcerative colitis, including the treatment of acute episodes and the maintenance of remission, as well as for the treatment of acute episodes of Crohn's disease. According to the company, the approval will further enrich the Group's product portfolio in the therapeutic area of the immune system.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CSPC Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime